3236 related articles for article (PubMed ID: 6966434)
21. Biological markers and breast cancer. A multiparametric study. II. Depressed immune competence.
Mandeville R; Lamoureux G; Legault-Poisson S; Poisson R
Cancer; 1982 Oct; 50(7):1280-8. PubMed ID: 6980699
[TBL] [Abstract][Full Text] [Related]
22. Clinical studies of methanol extraction residue fraction of Bacillus Calmette-Guérin as an immunostimulant in patients with advanced cancer.
Moertel CG; Ritts RE; Schutt AJ; Hahn RG
Cancer Res; 1975 Nov; 35(11 Pt 1):3075-83. PubMed ID: 1102082
[TBL] [Abstract][Full Text] [Related]
23. Suppressor cell activity in melanoma patients. I. Relation to tumor growth an immunoglobulin levels in vivo.
Werkmeister J; McCarthy W; Hersey P
Int J Cancer; 1981 Jul; 28(1):1-9. PubMed ID: 6458569
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy for melanoma.
Vaisrub S
JAMA; 1973 Sep; 225(10):1242. PubMed ID: 4542440
[No Abstract] [Full Text] [Related]
25. Immunologic defects in melanoma patients: lack of effect of BCG therapy.
Gersten MJ; Hadden EM; Kaplan MH; Pinsky CM; Armstrong D; Hadden JW
Clin Bull; 1977; 7(2):63-9. PubMed ID: 902403
[No Abstract] [Full Text] [Related]
26. Cellular and humoral systemic and mucosal immune responses stimulated in volunteers by an oral polybacterial immunomodulator "Dentavax".
Petrunov B; Marinova S; Markova R; Nenkov P; Nikolaeva S; Nikolova M; Taskov H; Cvetanov J
Int Immunopharmacol; 2006 Jul; 6(7):1181-93. PubMed ID: 16714223
[TBL] [Abstract][Full Text] [Related]
27. Immunologic function in humans before and after hyperthermia and chemotherapy for disseminated malignancy.
DeHoratius RJ; Hosea JM; Van Epps DE; Reed WP; Edwards WS; Williams RC
J Natl Cancer Inst; 1977 Apr; 58(4):905-11. PubMed ID: 300437
[TBL] [Abstract][Full Text] [Related]
28. Prolonged BCG treatment of melanoma: does it suppress the immune capacity?
Helander I; Nordman E; Häkkinen IP; Toivanen A
Br J Dermatol; 1979 Oct; 101(4):421-7. PubMed ID: 508607
[TBL] [Abstract][Full Text] [Related]
29. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
[TBL] [Abstract][Full Text] [Related]
30. Immune function during intravenous administration of a soybean oil emulsion.
Ota DM; Jessup JM; Babcock GF; Kirschbaum L; Mountain CF; McMurtrey MJ; Copeland EM
JPEN J Parenter Enteral Nutr; 1985; 9(1):23-7. PubMed ID: 3918196
[TBL] [Abstract][Full Text] [Related]
31. Humoral and cellular immunity in progressive systemic sclerosis.
Sierakowski S; Bernacka K
Med Interne; 1987; 25(4):233-8. PubMed ID: 3501150
[TBL] [Abstract][Full Text] [Related]
32. Prospects and limitations of systematic monitoring in patients with laryngeal cancer.
Brunetti F; Menzio P; Cortesina G; Sartoris A; Morra B; Bussi M
Acta Otolaryngol; 1979; 87(3-4):393-9. PubMed ID: 312588
[TBL] [Abstract][Full Text] [Related]
33. BCG stimulation of immune responsiveness in patients with malignant melanoma. Preliminary report.
Gutterman J; Mavligit G; McBride C; Frei E; Hersh EM
Cancer; 1973 Aug; 32(2):321-7. PubMed ID: 4722915
[No Abstract] [Full Text] [Related]
34. Cell-mediated and humoral types of immunologic immunity in idiopathic pancytopenia.
Traczyk Z; Orczyńska E; Cieśluk S
Arch Immunol Ther Exp (Warsz); 1979; 27(1-2):1-7. PubMed ID: 312631
[TBL] [Abstract][Full Text] [Related]
35. Lymphocyte function related to survival curves in patients with metastatic melanoma treated by chemoimmunotherapy.
Thatcher N; Palmer MK; Swindell R; Crowther D
Med Pediatr Oncol; 1978; 4(1):59-70. PubMed ID: 625264
[TBL] [Abstract][Full Text] [Related]
36. Benign monoclonal B cell lymphocytosis--a benign variant of CLL: clinical, immunologic, phenotypic, and cytogenetic studies in 20 patients.
Han T; Ozer H; Gavigan M; Gajera R; Minowada J; Bloom ML; Sadamori N; Sandberg AA; Gomez GA; Henderson ES
Blood; 1984 Jul; 64(1):244-52. PubMed ID: 6610446
[TBL] [Abstract][Full Text] [Related]
37. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Jan; 35(1):36-44. PubMed ID: 428146
[TBL] [Abstract][Full Text] [Related]
38. Immunology and cutaneous malignant melanoma.
Sober AJ
Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
[No Abstract] [Full Text] [Related]
39. Correlations among cutaneous reactivity to DNCB, PHA-induced lymphocyte blastogenesis and peripheral blood E rosettes.
Catalona WJ; Tarpley JL; Potvin C; Chretien PB
Clin Exp Immunol; 1975 Feb; 19(2):327-33. PubMed ID: 1082390
[TBL] [Abstract][Full Text] [Related]
40. The use of oral BCG in the treatment or metastatic malignant melanoma.
Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
